Thanks to both the tumor-specific expression pattern of EpCAM and the optimal pharmacokinetics and flexible manufacturability of DARPins, EpCAM-binding DARPins form a promising class of pan-carcinoma targeting agents. Here, EPCAM is linked to carcinoma.